Refining risk assessment in women with atypical hyperplasia
- First Online:
- 38 Downloads
Atypical hyperplasia (AH) is associated with an approximate fourfold increase in breast cancer risk. Although this increase in risk is significant, the majority of women with AH will not develop breast cancer. Current breast cancer risk prediction models are unable to provide accurate risk estimates for individuals with AH. Tamoxifen offers a substantive risk reduction for women with AH, but its profile of risks and side effects limits its acceptance and widespread use. Therefore, additional differentiation of breast cancer risk among women with AH is desirable. In addition to clinical factors (ie, age at AH diagnosis), recently investigated histologic features and molecular markers of an individual’s breast tissue show promise as features that further differentiate breast cancer risk in women with AH.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 30.Petroff BK, Phillips TA, Kimler BF, Fabian CJ: Detection of biomarker gene expression by real-time polymerase chain reaction using amplified ribonucleic acids from formalin-fixed random periareolar fine needle aspirates of human breast tissue. Anal Quant Cytol Histol 2006, 28:297–302.PubMedGoogle Scholar
- 37.Santisteban M, Reynolds C, Barr Fritcher EG, et al.: Ki67: a time varying biomarker of risk of breast cancer in atypical hyperplasia. Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 9–13, 2009.Google Scholar